Company Description

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases.

The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.

It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions.

BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

BioLineRx Ltd.

Country	Israel
Founded	2003
IPO Date	Jul 25, 2011
Industry	Biotechnology
Sector	Healthcare
Employees	79
CEO	Philip Serlin

Contact Details

Address: Modi’in Technology Park, 2 HaMa’ayan Street Hevel Modi'in, 7177871 Israel
Phone	972 8 642 9100
Website	biolinerx.com

Stock Details

Ticker Symbol	BLRX
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001498403
CUSIP Number	09071M205
ISIN Number	US09071M2052
SIC Code	2834

Key Executives

Name	Position
Philip Serlin	Chief Executive Officer
Mali Zeevi	Chief Financial Officer
John Lacey	Head of Investor Relations

Latest SEC Filings

Date	Type	Title
Dec 27, 2024	S-8	Securities to be offered to employees in employee benefit plans
Nov 25, 2024	6-K	Report of foreign issuer
Nov 21, 2024	6-K	Report of foreign issuer
Nov 21, 2024	424B5	Filing
Nov 12, 2024	6-K	Report of foreign issuer
Nov 5, 2024	6-K	Report of foreign issuer
Oct 16, 2024	6-K	Report of foreign issuer
Oct 1, 2024	6-K	Report of foreign issuer
Aug 19, 2024	6-K	Report of foreign issuer
Aug 15, 2024	6-K	Report of foreign issuer

View All SEC Filings